公开(公告)号：EP4000617A1

公开(公告)日：2022-05-25

申请号：EP20383021.1

申请日：2020-11-23

申请人： Fundació Institut de Recerca Contra la Leucèmia Josep Carreras

发明人： MUÑOZ RISUEÑO, Ruth ,  CORNET MASANA, Josep Maria ,  CARBÓ MARQUÉS, José María

IPC分类号： A61K31/381 ,  A61K31/4535 ,  A61K31/496 ,  A61P35/02

摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human subject, having leukaemia, preferably acute myeloid leukemia (AML), B and T acute lymphoblastic leukemias (B-ALL and T-ALL), or chronic myeloid leukemia (CML), or a lymphoma or a solid tumour, comprising administering to said animal a therapeutically effective amount of a compound having any of the formulae identified throughout the present specification, optionally together or in combination with a conventional compound or compound mixture useful in any of said treatments, in particular a topoisomerase II inhibitor, an antimetabolite, or an antitumor antibiotic, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said compound.